UPDATE: Mylan Issues Comment on Teva Deal to Buy Allergan's Generic Drug Unit

Loading...
Loading...
Mylan N.V.
MYL
today issued the following statement regarding Teva's (NYSE and TASE: TEVA) announcement of its entry into an agreement to acquire Allergan's Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan. Mylan Executive Chairman Robert J. Coury stated: "We congratulate Teva on their agreement to acquire Allergan's generics business and welcome their continued, and potentially enhanced, commitment to the generics industry. As Teva continues to move forward with their strategy, Mylan's strategic focus remains unchanged. "Mylan's Board and leadership team remains steadfast in its commitment to our mission, vision and strategy to provide access to quality medicine to the world's 7 billion people and deliver value and sustainable growth for our shareholders and other stakeholders. Our offer to acquire Perrigo continues to be the next natural step in this strategy. Combining Mylan and Perrigo will create a unique infrastructure that is able to maximize on evolving industry dynamics and capitalize on key trends. Further, the complementary cultures and strategies of these two businesses will enable us to redefine how healthcare is delivered and position our company for the future. "We look forward to the next step in the process to make our combination with Perrigo a reality – the vote by Mylan shareholders to support this transaction – which we expect to occur in the next several weeks."
Loading...
Loading...
Posted In: NewsM&APress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...